Technical Articles

This article systematically elaborates on the molecular structure and expression patterns of CD22 (Siglec-2) as a member of the immunoglobulin superfamily, analyzes its core function in the negative regulation of B-cell signaling and its phase-specific expression characteristics during B-cell development, explores its potential as a therapeutic target in B-cell malignancies and autoimmune diseases as well as the biomarker potential of soluble CD22, and introduces the detection applications of fluorescently labeled recombinant proteins based on these findings.